Jasper Therapeutics Inc JSPR shares are trading higher by 13.21% to $1.80 Tuesday morning after the company announced development prioritization of briquilimab in chronic diseases and stem cell transplant for rare diseases.
As part of an overall portfolio prioritization, Jasper Therapeutics will focus on the development of its lead product candidate, briquilimab, in chronic diseases and stem cell transplant for rare diseases.
Jasper says this portfolio includes a new program on chronic urticaria, along with the company's existing programs for lower-risk myelodysplastic syndrome (MDS), sickle cell disease, Fanconi anemia and severe combined immunodeficiency (SCID).
See Also: Why Broadcom Shares Are Diving Following Apple News
"We are ecstatic about the growing body of clinical and scientific evidence that show briquilimab has an attractive tolerability profile in a number of potential indications and may provide clinically meaningful results for a wide range of patients, and are grateful to our team, clinical investigators, patients and external partners for helping us advance this drug into later stage trials so quickly in such a challenging environment over the past two years," said Ronald Martell, President and CEO of Jasper.
According to data from Benzinga Pro, JSPR has a 52-week high of $7.06 and a 52-week low of $0.39.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
